Genetico invests in Heart Drug Developer

Genetico is investing 50 million rubles in the startup Cardiogenex, which develops gene therapy drugs for the treatment of hereditary heart diseases. Startup uses the funds received to validate models of cardiomyopathic diseases, conduct animal studies to select the most effective candidate drugs for preclinical research. There are about 730,000 people with hypertrophic cardiomyopathy in Russia, and existing medications have only a symptomatic effect.